1
|
Mirzaaghaei S, Foroughmand AM, Saki G, Shafiei M. Combination of Epigallocatechin-3-gallate and Silibinin: A Novel Approach for Targeting Both Tumor and Endothelial Cells. ACS OMEGA 2019; 4:8421-8430. [PMID: 31459931 PMCID: PMC6648523 DOI: 10.1021/acsomega.9b00224] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Accepted: 04/30/2019] [Indexed: 05/05/2023]
Abstract
Despite promising benefits, anti-angiogenic strategies have revealed several drawbacks, which necessitate development of novel approaches in cancer therapy strategies including non-small-cell lung cancer, as one of the leading causes of cancer death, all over the world. Combination of flavonoids could be a safe and effective option to synergize their impact on mechanisms controlling tumor angiogenesis. In this study, we have investigated the plausible synergism of epigallocatechin-3-gallate (EGCG) and silibinin on endothelial cells, for the first time. Cell viability and migration were evaluated by survival and wound healing assays, respectively. Then, we assessed the expression of VEGF, VEGFR2, and miR-17-92 cluster using real-time polymerase chain reaction in endothelial-tumor cell and endothelial-fibroblast coculture models. EGCG ± silibinin suppressed endothelial and lung tumor cell migration in lower than 50% toxic doses. VEGF, VEGFR2, and pro-angiogenic members of the miR-17-92 cluster were downregulated upon treatments. Specifically, the combination treatment upregulated an anti-angiogenic member of the cluster, miR-19b. Our data provides evidence to utilize the EGCG and silibinin combination as a novel approach to target tumor angiogenesis in the future.
Collapse
Affiliation(s)
- Somaye Mirzaaghaei
- Department
of Genetics, Faculty of Science, Shahid
Chamran University of Ahvaz, Golestan Boulevard, Ahvaz 6135783151, Iran
| | - Ali M. Foroughmand
- Department
of Genetics, Faculty of Science, Shahid
Chamran University of Ahvaz, Golestan Boulevard, Ahvaz 6135783151, Iran
| | - Ghasem Saki
- Department
of Anatomical Sciences, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 6135715794, Iran
| | - Mohammad Shafiei
- Department
of Genetics, Faculty of Science, Shahid
Chamran University of Ahvaz, Golestan Boulevard, Ahvaz 6135783151, Iran
| |
Collapse
|
2
|
Liu X, Chen L, Zhang T. Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma. Cancer Control 2018; 25:1073274818778001. [PMID: 29843532 PMCID: PMC6028180 DOI: 10.1177/1073274818778001] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Golgi membrane protein 1 (GOLM1) is a transmembrane glycoprotein of the Golgi cisternae, which is implicated in carcinogenesis of multiple types of cancer. In this study, using data from the Gene Expression Omnibus and The Cancer Genome Atlas, we compared the expression of GOLM1 in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) and studied its prognostic value in terms of overall survival (OS) and recurrence-free survival (RFS) in these 2 subtypes of non-small cell lung cancer (NSCLC). Results showed that GOLM1 was significantly upregulated in both LUAD and LUSC tissues compared to the normal controls. However, GOLM1 expression was higher in LUAD tissues than in LUSC tissues. More importantly, using over 10 years’ survival data from 502 patients with LUAD and 494 patients with LUSC, we found that high GOLM1 expression was associated with unfavorable OS and RFS in patients with LUAD, but not in patients with LUSC. The following univariate and multivariate analyses confirmed that increased GOLM1 expression was an independent prognostic indicator of poor OS (hazard ratio [HR]: 1.30, 95% confidence interval [CI]: 1.11-1.54, P = .002) and RFS (HR: 1.37, 95% CI: 1.14-1.64, P = .001) in patients with LUAD. Of 511 cases with LUAD, 248 (48.5%) had heterozygous loss (−1), while 28 (5.5%) of 511 cases with LUAD had low-level copy gain (+1). In addition, we also found that the methylation status of 1 CpG site (chr9: 88,694,942-88,694,944) showed a weak negative correlation with GOLM1 expression (Pearson r = −0.25). Based on these findings, we infer that GOLM1 might serve as a valuable prognostic biomarker in LUAD, but not in LUSC. In addition, DNA copy number alterations and methylation might be 2 important mechanisms of dysregulated GOLM1 in LUAD.
Collapse
Affiliation(s)
- Xi Liu
- 1 Department of Thoracic Surgery, Chinese PLA General Hospital, Beijing, People's Republic of China
| | - Lei Chen
- 1 Department of Thoracic Surgery, Chinese PLA General Hospital, Beijing, People's Republic of China
| | - Tao Zhang
- 1 Department of Thoracic Surgery, Chinese PLA General Hospital, Beijing, People's Republic of China
| |
Collapse
|
3
|
Kaishang Z, Xue P, Shaozhong Z, Yingying F, Yan Z, Chanjun S, Zhenzhen L, Xiangnan L. Elevated expression of Twinfilin-1 is correlated with inferior prognosis of lung adenocarcinoma. Life Sci 2018; 215:159-169. [PMID: 30391462 DOI: 10.1016/j.lfs.2018.10.067] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2018] [Revised: 10/22/2018] [Accepted: 10/29/2018] [Indexed: 02/07/2023]
Abstract
AIM Twinfilin-1 (TWF1) has been implicated in cell motility, invasion and migration. However, its exact role in lung cancer progression is still unclear. In the present study, we explored clinical and prognostic relevance of Twinfilin-1 (TWF1) levels for non-small cell lung carcinoma (NSCLC). MAIN METHODS The Cancer Genome Atlas (TCGA) dataset was analyzed for possible association between TWF1 expressions in NSCLC tissues and patient prognosis. The meta-analysis data was validated in our clinical study through techniques of immunoblotting, expression analysis and immunohistochemistry. KEY FINDINGS Lung adenocarcinoma (LUAD) as well as lung squamous cell carcinoma (LUSC) showed significantly elevated expression of TWF1 compared to normal lung tissues. Univariate Cox regression analysis showed high expression of TWF1 to be independent prognostic indicator involved in overall survival (hazard ratio: 1.636; 95% CI: 1.223-2.189) and recurrence-free survival (hazard ratio: 1.551; 95% CI: 1.158-2.077) in LUAD, but not in LUSC. Similar trend was found in our clinical study. LUAD tissues reflected TWF1 overexpression to be positively correlated with grade of tumor, size and lymph node metastasis. Enhanced TWF1 expression was identified to be an independent predictor for the disadvantageous prognosis of LUAD through simultaneously both univariate as well as multivariate Cox regression analyses (both p < 0.05). Kaplan-Meier survival graphs further corroborated that poor disease prediction in the patients with LUAD was indicated through high TWF1 expression (p = 0.028). SIGNIFICANCE Robustness and poor prognosis in LUAD correlated with TWF1 levels thus making it a suitable therapeutic target against LUAD.
Collapse
Affiliation(s)
- Zhang Kaishang
- Thoracic Surgery Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Pan Xue
- Thoracic Surgery Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Zheng Shaozhong
- Thoracic Surgery Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Fan Yingying
- Thoracic Surgery Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Zhang Yan
- Thoracic Surgery Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Sun Chanjun
- Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Li Zhenzhen
- Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
| | - Li Xiangnan
- Thoracic Surgery Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
| |
Collapse
|
4
|
Yu C, Hou L, Cui H, Zhang L, Tan X, Leng X, Li Y. LDHA upregulation independently predicts poor survival in lung adenocarcinoma, but not in lung squamous cell carcinoma. Future Oncol 2018; 14:2483-2492. [PMID: 29756998 DOI: 10.2217/fon-2018-0177] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Aim: To investigate the potential prognostic value of LDHA in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Patients & methods: Molecular, clinicopathological and survival data in Cancer Genome Atlas-Lung Cancer were obtained for secondary analysis. Results: LDHA expression was significantly upregulated in both LUAD and LUSC compared with normal lung tissues. LUSC tissues had even higher LDHA expression compared with LUAD tissues. Increased LDHA expression was an independent prognostic indicator in terms of overall survival (hazard ratio: 1.547, 95% CI: 1.253–1.911; p < 0.001) and recurrence-free survival (hazard ratio: 1.486, 95% CI: 1.161–1.900; p = 0.002) in LUAD, but not in LUSC. Conclusion: LDHA expression might only serve as an independent prognostic indicator of unfavorable overall survival and recurrence-free survival in LUAD, but not in LUSC.
Collapse
Affiliation(s)
- Chengyong Yu
- Clinical Laboratory, Weihai Central Hospital, Weihai 264400, Shandong, PR China
| | - Liyan Hou
- Department of Pharmacy, Weihai Central Hospital, Weihai 264400, Shandong, PR China
| | - Hailing Cui
- Clinical Laboratory, Weihai Central Hospital, Weihai 264400, Shandong, PR China
| | - Liyan Zhang
- Clinical Laboratory, Weihai Central Hospital, Weihai 264400, Shandong, PR China
| | - Xiaodong Tan
- Clinical Laboratory, Weihai Central Hospital, Weihai 264400, Shandong, PR China
| | - Xuejiao Leng
- Clinical Laboratory, Weihai Central Hospital, Weihai 264400, Shandong, PR China
| | - Yingbo Li
- Department of Blood Transfusion, Weihai Central Hospital, Weihai 264400, Shandong, PR China
| |
Collapse
|
5
|
Chen J, Chen H, Yang H, Dai H. SPC25 upregulation increases cancer stem cell properties in non-small cell lung adenocarcinoma cells and independently predicts poor survival. Biomed Pharmacother 2018; 100:233-239. [PMID: 29432994 DOI: 10.1016/j.biopha.2018.02.015] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2017] [Revised: 02/01/2018] [Accepted: 02/02/2018] [Indexed: 11/15/2022] Open
Abstract
In this study, we investigated the functional role and prognostic value of spindle pole body component 25 (SPC25) in non-small cell lung cancer (NSCLC). SPC25 expression profile in lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC) and normal lung tissues was examined by using data from the Cancer Genome Atlas (TCGA) and the Human Protein Atlas (HPA). LUAD A549 cells and LUSC H520 cells were used to investigate the influence of SPC25 on cancer stem cell (CSC) properties in terms of the proportion of CD133+ cells, tumorsphere formation and CSC markers, including CD133, ALDH1 and Sox2. Data mining was also performed in the Kaplan-Meier plotter and TCGA-NSCLC to assess the independent prognostic value of SPC25. Results showed SPC25 was significantly upregulated in LUAD and LUSC tissues compared with normal lung tissues. SPC25 overexpression significantly increased the CSC properties and invasion of A549 cells, but not H520 cells. In comparison, SPC25 knockdown impaired the CSC properties and invasion of A549 cells, but not H520 cells. Univariate and multivariate analysis confirmed that high SPC25 expression was an independent prognostic factor for poor overall survival (OS) (HR: 1.622, 95%CI: 1.207-2.178, p = .001) and recurrence-free survival (RFS) (HR: 1.726, 95%CI: 1.242-2.399, p = .001) in LUAD patients. However, no independent prognostic value of SPC25 was observed in LUSC patients even under the best cut-off model. Based on these findings, we infer that SPC25 upregulation can increase CSC properties in LUAD and independently predict poor survival in this histological subtype.
Collapse
Affiliation(s)
- Jingxia Chen
- Department of Emergency Medicine, The Affiliated Hospital of Weifang Medical University, Weifang, Shandong, 261031, China
| | - Hongfen Chen
- Department of Emergency Medicine, The Affiliated Hospital of Weifang Medical University, Weifang, Shandong, 261031, China.
| | - Hanbing Yang
- Department of Emergency Medicine, The Affiliated Hospital of Weifang Medical University, Weifang, Shandong, 261031, China
| | - Huizhen Dai
- Department of Emergency Medicine, The Affiliated Hospital of Weifang Medical University, Weifang, Shandong, 261031, China
| |
Collapse
|
6
|
High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma. PLoS One 2017; 12:e0187356. [PMID: 29088286 PMCID: PMC5663495 DOI: 10.1371/journal.pone.0187356] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Accepted: 10/18/2017] [Indexed: 02/05/2023] Open
Abstract
Different subtypes of non-small cell lung cancer (NSCLC) have distinct sites of origin, histologies, genetic and epigenetic changes. In this study, we explored the mechanisms of ECT2 dysregulation and compared its prognostic value in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). In addition, we also investigated the enrichment of ECT2 co-expressed genes in KEGG pathways in LUAD and LUSC. Bioinformatic analysis was performed based on data from the Cancer Genome Atlas (TCGA)-LUAD and TCGA-LUSC. Results showed that ECT2 expression was significantly upregulated in both LUAD and LUSC compared with normal lung tissues. ECT2 expression was considerably higher in LUSC than in LUAD. The level of ECT2 DNA methylation was significantly lower in LUSC than in LUAD. ECT2 mutation was observed in 5% of LUAD and in 51% of LUSC cases. Amplification was the predominant alteration. LUAD patients with ECT2 amplification had significantly worse disease-free survival (p = 0.022). High ECT2 expression was associated with unfavorable overall survival (OS) (p<0.0001) and recurrence-free survival (RFS) (p = 0.001) in LUAD patients. Nevertheless, these associations were not observed in patients with LUSC. The following univariate and multivariate analysis showed that the high ECT2 expression was an independent prognostic factor for poor OS (HR: 2.039, 95%CI: 1.457–2.852, p<0.001) and RFS (HR: 1.715, 95%CI: 1.210–2.432, p = 0.002) in LUAD patients, but not in LUSC patients. Among 518 genes co-expressed with ECT2 in LUAD and 386 genes co-expressed with ECT2 in LUSC, there were only 98 genes in the overlapping cluster. Some of the genes related KEGG pathways in LUAD were not observed in LUSC. These differences might help to explain the different prognostic value of ECT2 in LUAD and LUSC, which are also worthy of further studies.
Collapse
|
7
|
Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non-small-cell Lung Cancer. MOLECULAR THERAPY-NUCLEIC ACIDS 2016; 5:e384. [PMID: 27845769 PMCID: PMC5155322 DOI: 10.1038/mtna.2016.90] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Accepted: 09/08/2016] [Indexed: 12/29/2022]
Abstract
Lung cancer is the leading cause of cancer deaths in both men and women in the United States accounting for about 27% of all cancer deceases. In our effort to develop newer therapy for lung cancer, we evaluated the combinatory antitumor effect of siRNA targeting VEGF and the PI3K/mTOR dual inhibitor PF-04691502. We analyzed the anticancer effect of siRNA VEGF and PF-04691502 combination on proliferation, colony formation and migration of A549 and H460 lung cancer cells. Additionally, we assessed the combination treatment antiangiogenic effect on human umbilical vein endothelial cells. Here, we show for the first time that the antiangiogenic siRNA VEGF potentiates the PF-04691502 anticancer activity against non–small-cell lung cancer. We observed a significant (P < 0.05) decrease in cell viability, colony formation, and migration for the combination comparing with the single drug treatment. We also showed a significant (P < 0.05) enhanced effect of the combination treatment inhibiting angiogenesis progression and tube formation organization compared to the single drug treatment groups. Our findings demonstrated an enhanced synergistic anticancer effect of siRNA VEGF and PF-04691502 combination therapy by targeting two main pathways involved in lung cancer cell survival and angiogenesis which will be useful for future preclinical studies and potentially for lung cancer patient management.
Collapse
|
8
|
Stefanou D, Stamatopoulou S, Sakellaropoulou A, Akakios G, Gkiaouraki M, Gkeka D, Prevezanou M, Ardavanis A. Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases. Oncol Lett 2016; 12:4635-4642. [PMID: 28101218 DOI: 10.3892/ol.2016.5268] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2015] [Accepted: 04/05/2016] [Indexed: 01/16/2023] Open
Abstract
Data concerning bevacizumab plus pemetrexed plus carboplatin as first-line treatment for patients with non-squamous non-small cell lung cancer (NSCLC) with or without brain metastases (BM) are lacking. The present study analyzed the efficacy and safety of this combination as induction therapy, followed by maintenance therapy with bevacizumab plus pemetrexed in non-squamous NSCLC patients with or without BM. Treatment-naïve patients with advanced non-squamous NSCLC and an Eastern Cooperative Oncology Group performance status score of 0-2 were eligible. Treatment consisted of carboplatin (area under the curve of 5), pemetrexed (500 mg/m2) and bevacizumab (15 mg/kg) every 3 weeks for 6 cycles. Responders and patients with stable disease received maintenance therapy with bevacizumab plus pemetrexed until disease progression, which was evaluated every 3 cycles, or unacceptable toxicity. Kaplan-Meier median progression-free survival (PFS) and overall survival (OS) times were the primary endpoints, and safety was the secondary endpoint. In total, 39 patients, aged 44-78 years (median, 60 years), were treated; 11 (28.2%) of whom presented with BM. The majority of patients (56.4%) completed 6 cycles of induction therapy, and 26 patients continued on to maintenance therapy. The median PFS time was 8.2 months [95% confidence interval (CI), 7.05-9.35] and the median OS time was 14.0 months (95% CI, 8.46-19.54). Median PFS and OS times did not differ significantly between patients with or without BM (log rank (Mantel-Cox): PFS, P=0.748 and OS, P=0.447). The majority of patients (76.9%) did not experience adverse events during treatment. Overall, bevacizumab plus pemetrexed plus carboplatin as induction therapy, followed by bevacizumab plus pemetrexed as maintenance therapy was effective and well tolerated in advanced NSCLC, whether brain metastases were present or not.
Collapse
Affiliation(s)
- Dimitra Stefanou
- First Department of Medical Oncology, St. Savas Anticancer Hospital, Athens 115 22, Greece
| | - Sofia Stamatopoulou
- First Department of Medical Oncology, St. Savas Anticancer Hospital, Athens 115 22, Greece
| | | | - Gavriil Akakios
- First Department of Medical Oncology, St. Savas Anticancer Hospital, Athens 115 22, Greece
| | - Marina Gkiaouraki
- First Department of Medical Oncology, St. Savas Anticancer Hospital, Athens 115 22, Greece
| | - Despina Gkeka
- First Department of Medical Oncology, St. Savas Anticancer Hospital, Athens 115 22, Greece
| | - Maria Prevezanou
- First Department of Medical Oncology, St. Savas Anticancer Hospital, Athens 115 22, Greece
| | - Alexandros Ardavanis
- First Department of Medical Oncology, St. Savas Anticancer Hospital, Athens 115 22, Greece
| |
Collapse
|
9
|
Strauch LS, Eriksen RØ, Sandgaard M, Kristensen TS, Nielsen MB, Lauridsen CA. Assessing Tumor Response to Treatment in Patients with Lung Cancer Using Dynamic Contrast-Enhanced CT. Diagnostics (Basel) 2016; 6:diagnostics6030028. [PMID: 27455330 PMCID: PMC5039562 DOI: 10.3390/diagnostics6030028] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2016] [Revised: 07/12/2016] [Accepted: 07/15/2016] [Indexed: 12/23/2022] Open
Abstract
The aim of this study was to provide an overview of the literature available on dynamic contrast-enhanced computed tomography (DCE-CT) as a tool to evaluate treatment response in patients with lung cancer. This systematic review was compiled according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Only original research articles concerning treatment response in patients with lung cancer assessed with DCE-CT were included. To assess the validity of each study we implemented Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). The initial search yielded 651 publications, and 16 articles were included in this study. The articles were divided into groups of treatment. In studies where patients were treated with systemic chemotherapy with or without anti-angiogenic drugs, four out of the seven studies found a significant decrease in permeability after treatment. Four out of five studies that measured blood flow post anti-angiogenic treatments found that blood flow was significantly decreased. DCE-CT may be a useful tool in assessing treatment response in patients with lung cancer. It seems that particularly permeability and blood flow are important perfusion values for predicting treatment outcome. However, the heterogeneity in scan protocols, scan parameters, and time between scans makes it difficult to compare the included studies.
Collapse
Affiliation(s)
- Louise S Strauch
- Department of Diagnostic Radiology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
- Department of Technology, Faculty of Health and Technology, Metropolitan University College, 2200 Copenhagen, Denmark.
| | - Rie Ø Eriksen
- Department of Diagnostic Radiology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
- Department of Technology, Faculty of Health and Technology, Metropolitan University College, 2200 Copenhagen, Denmark.
| | - Michael Sandgaard
- Department of Diagnostic Radiology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
| | - Thomas S Kristensen
- Department of Diagnostic Radiology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
| | - Michael B Nielsen
- Department of Diagnostic Radiology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
| | - Carsten A Lauridsen
- Department of Diagnostic Radiology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
- Department of Technology, Faculty of Health and Technology, Metropolitan University College, 2200 Copenhagen, Denmark.
| |
Collapse
|
10
|
Martínez E, Martínez M, Rico M, Hernández B, Casas F, Viñolas N, Pérez-Casas A, Dómine M, Mínguez J. Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a Phase II trial. Onco Targets Ther 2016; 9:1057-66. [PMID: 27042098 PMCID: PMC4780183 DOI: 10.2147/ott.s89755] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Purpose Although many studies have confirmed the synergic effects of combining chemotherapy (CT) and radiotherapy (RT), clinical data evaluating safety and efficacy of erlotinib in combination with RT in locally advanced non-small-cell lung cancer (NSCLC) are limited. The aim of this study was to determine the feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to the standard three-dimensional conformal thoracic RT in patients with unresectable or locally advanced NSCLC who are not candidates for receiving standard CT. Patients and methods Feasibility and tolerability, assessed by evaluating adverse events (AEs), and effectiveness, by calculating progression-free survival (PFS), overall survival (OS), cancer-specific survival (CSS), and objective response rate (ORR), were analyzed in 30 patients receiving RT alone and 60 receiving RT and erlotinib. Results Erlotinib with RT showed an extended CSS and a higher rate of complete responses compared with RT alone. No differences between groups were found regarding OS, PFS, and ORR. AEs were significantly higher in the combined treatment, which mainly included cutaneous toxicity, dyspnea, fatigue, hyporexia, diarrhea, and infection. Erlotinib did not increase the toxicity produced by RT. Conclusion The combination of erlotinib with RT produced, in our study, a scarce clinical benefit in the treatment of unresectable or locally advanced NSCLC, limited to complete responses and longer CSS rate compared with RT alone. Increased toxicity events were associated with combined therapy, which mainly included cutaneous toxicity. In our opinion, further studies in molecularly unselected lung cancer patients treated with EGFR TKIs and RT are not indicated. The use of biomarkers for the identification of patients that are most likely to benefit from this treatment is an essential next step in the research of this condition.
Collapse
Affiliation(s)
- Enrique Martínez
- Radiation Oncology Services, Hospital of Navarra, Pamplona, Spain
| | - Maite Martínez
- Radiation Oncology Services, Hospital of Navarra, Pamplona, Spain
| | - Mikel Rico
- Radiation Oncology Services, Hospital of Navarra, Pamplona, Spain
| | - Berta Hernández
- Radiation Oncology Services, Hospital of Navarra, Pamplona, Spain
| | - Francesc Casas
- Medical Oncology Department, Clinical Hospital of Barcelona, Barcelona, Spain
| | - Nuria Viñolas
- Medical Oncology Department, Clinical Hospital of Barcelona, Barcelona, Spain
| | - Ana Pérez-Casas
- Department of Radiation Oncology, Jiménez Díaz Foundation, Madrid, Spain
| | - Manuel Dómine
- Department of Radiation Oncology, Jiménez Díaz Foundation, Madrid, Spain
| | - Julián Mínguez
- Department of Radiation Oncology, University Hospital of Donostia, San Sebastian, Spain
| |
Collapse
|
11
|
Coelho AL, Araújo AM, Gomes MP, Catarino RJ, Andrade EB, Lopes AM, Medeiros RM. Combined Ang-2 and VEGF serum levels: holding hands as a new integral biomarker in non-small-cell lung cancers. Future Oncol 2015; 11:3233-42. [PMID: 26562248 DOI: 10.2217/fon.15.207] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
AIM Evaluate if serum levels of VEGF and Ang-2 are correlated in non-small-cell lung cancers (NSCLCs) and its implications in the diagnostic and prognostic of the disease. PATIENTS & METHODS Unselected cohort of 145 NSCLC patients and 30 control individuals. The serum levels of Ang-2 and VEGF of each patient were measured by ELISA prior to treatment. RESULTS & CONCLUSIONS Serum levels of Ang-2 and VEGF are correlated (p < 0.0001). High serum levels of Ang-2 and VEGF isolated and both combined (high(Ang-2/VEGF)) correlate with likelihood of presenting NSCLC (p = 0.016; p = 0.003; p < 0.0001, respectively). Serum levels of Ang-2 and high(Ang-2/VEGF) but not VEGF alone are independent prognostic factors (p = 0.001; p = 0.619; p = 0.005). High(Ang-2/VEGF) serum levels could be exploited as a new valuable integral biomarker in NSCLC.
Collapse
Affiliation(s)
- Ana Luísa Coelho
- Instituto Português de Oncologia - Porto, Molecular Oncology Group, Portugal.,Faculdade de Medicina - University of Porto, Porto, Portugal
| | - António Manuel Araújo
- Centro Hospitalar do Porto - Medical Oncology Department, Porto, Portugal.,Instituto de Ciências Biomédicas Abel Salazar - University of Porto, Porto, Portugal
| | - Mónica Patrícia Gomes
- Instituto Português de Oncologia - Porto, Molecular Oncology Group, Portugal.,Instituto de Ciências Biomédicas Abel Salazar - University of Porto, Porto, Portugal
| | - Raquel Jorge Catarino
- Instituto Português de Oncologia - Porto, Molecular Oncology Group, Portugal.,Instituto de Ciências Biomédicas Abel Salazar - University of Porto, Porto, Portugal
| | - Elva Bonifácio Andrade
- Instituto de Biologia Molecular e Celular - Immunobiology Research Group, Porto, Portugal
| | - Agostinho Marques Lopes
- Faculdade de Medicina - University of Porto, Porto, Portugal.,Centro Hospitalar de S. João - Pulmonology Department, Porto, Portugal
| | - Rui Manuel Medeiros
- Instituto Português de Oncologia - Porto, Molecular Oncology Group, Portugal.,Instituto de Ciências Biomédicas Abel Salazar - University of Porto, Porto, Portugal.,Liga Portuguesa Contra o Cancro (NRNorte) - Research Department, Porto, Portugal
| |
Collapse
|
12
|
Huang C, Wang X, Wang J, Lin L, Liu Z, Xu W, Wang L, Xiao J, Li K. Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor. Thorac Cancer 2014; 5:438-46. [PMID: 26767036 DOI: 10.1111/1759-7714.12115] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2014] [Accepted: 03/19/2014] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Antiangiogenesis plays a key role in the treatment of non-small lung cancer (NSCLC). We observed the cavitation of lesions in patients with stage IIIB/IV NSCLC treated with Endostar and vinorelbine-cisplatin (NP) chemotherapy, and evaluated the imaging characteristics and clinical outcome of patients who developed tumor cavitation. METHODS Our study included 105 untreated NSCLC patients who received Endostar in combination with NP chemotherapy at the Tianjin Lung Cancer Center. Chest computed tomography (CT) was performed to evaluate the efficacy every two cycles. The number of activated circulating endothelial cells (aCECs) was measured by flow cytometry. Rates of tumor cavitation were documented and their clinical CT imaging data were analyzed. RESULTS Tumor cavitation occurred in 11 of the 105 (10.5%) patients treated with Endostar and NP. The response rates were 37.2% (35/94) in patients without cavitation, 27.3% (3/11) evaluated by Response Evaluation Criteria in Solid Tumors, and 100.0% (11/11) if evaluated by an alternate method in patients who developed cavitation. Three of the 11 cases with cavitation had a centrally located tumor. No patients had hemoptysis or any other severe side effects. Compared with patients not developing cavitation, cavity formation resulted in a longer median survival time (13.6 vs. 11.8 months, P = 0.011) and an increase in the number of aCECs (244.4/10(5) vs. 23.3/10(5), P = 0.000). CONCLUSIONS Intratumoral cavitation induced by Endostar is common in NSCLC patients, and is not correlated with squamous histology, tumor location or pulmonary hemorrhage. Cavitation might have a significant effect on the number of aCECs and overall prognosis.
Collapse
Affiliation(s)
- Chun Huang
- Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer Tianjin, China
| | - Xuan Wang
- Department of Nutrition and Food Science, School of Public Health, Tianjin Medical University Tianjin, China; Department of Pathology, Tianjin Medical University Cancer Institute and Hospital Tianjin, China
| | - Jing Wang
- Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer Tianjin, China
| | - Li Lin
- Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer Tianjin, China
| | - Zhujun Liu
- Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer Tianjin, China
| | - Wenjing Xu
- Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer Tianjin, China
| | - Liuchun Wang
- Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer Tianjin, China
| | - Jianyu Xiao
- Department of Diagnostic Radiology, Tianjin Medical University Cancer Institute and Hospital Tianjin, China
| | - Kai Li
- Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer Tianjin, China
| |
Collapse
|
13
|
Tertil M, Skrzypek K, Florczyk U, Weglarczyk K, Was H, Collet G, Guichard A, Gil T, Kuzdzal J, Jozkowicz A, Kieda C, Pichon C, Dulak J. Regulation and novel action of thymidine phosphorylase in non-small cell lung cancer: crosstalk with Nrf2 and HO-1. PLoS One 2014; 9:e97070. [PMID: 24819505 PMCID: PMC4018251 DOI: 10.1371/journal.pone.0097070] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2013] [Accepted: 04/14/2014] [Indexed: 02/01/2023] Open
Abstract
Proangiogenic enzyme thymidine phosphorylase (TP) is a promising target for anticancer therapy, yet its action in non-small cell lung carcinoma (NSCLC) is not fully understood. To elucidate its role in NSCLC tumor growth, NCI-H292 lung mucoepidermoid carcinoma cells and endothelial cells were engineered to overexpress TP by viral vector transduction. NSCLC cells with altered expression of transcription factor Nrf2 or its target gene heme oxygenase-1 (HO-1) were used to study the regulation of TP and the findings from pre-clinical models were related to gene expression data from clinical NSCLC specimens. Overexpression of Nrf2 or HO-1 resulted in upregulation of TP in NCI-H292 cells, an effect mimicked by treatment with an antioxidant N-acetylcysteine and partially reversed by HO-1 knockdown. Overexpression of TP attenuated cell proliferation and migration in vitro, but simultaneously enhanced angiogenic potential of cancer cells supplemented with thymidine. The latter was also observed for SK-MES-1 squamous cell carcinoma and NCI-H460 large cell carcinoma cells. TP-overexpressing NCI-H292 tumors in vivo exhibited better oxygenation and higher expression of IL-8, IL-1β and IL-6. TP overexpression in endothelial cells augmented their angiogenic properties which was associated with enhanced generation of HO-1 and VEGF. Correlation of TP with the expression of HO-1 and inflammatory cytokines was confirmed in clinical samples of NSCLC. Altogether, the increased expression of IL-1β and IL-6 together with proangiogenic effects of TP-expressing NSCLC on endothelium can contribute to tumor growth, implying TP as a target for antiangiogenesis in NSCLC.
Collapse
Affiliation(s)
- Magdalena Tertil
- Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland
- Centre de Biophysique Moleculaire, CNRS UPR4301, Orléans, France
- Department of Molecular Neuropharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
| | - Klaudia Skrzypek
- Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland
- Centre de Biophysique Moleculaire, CNRS UPR4301, Orléans, France
| | - Urszula Florczyk
- Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland
| | | | - Halina Was
- Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland
| | - Guillaume Collet
- Centre de Biophysique Moleculaire, CNRS UPR4301, Orléans, France
| | - Alan Guichard
- Centre de Biophysique Moleculaire, CNRS UPR4301, Orléans, France
| | - Tomasz Gil
- Department of Thoracic Surgery, Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland
| | - Jaroslaw Kuzdzal
- Department of Thoracic Surgery, Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland
| | - Alicja Jozkowicz
- Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland
| | - Claudine Kieda
- Centre de Biophysique Moleculaire, CNRS UPR4301, Orléans, France
| | - Chantal Pichon
- Centre de Biophysique Moleculaire, CNRS UPR4301, Orléans, France
| | - Jozef Dulak
- Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland
- * E-mail:
| |
Collapse
|
14
|
Theranostic tumor homing nanocarriers for the treatment of lung cancer. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2013; 10:1053-63. [PMID: 24355163 DOI: 10.1016/j.nano.2013.12.002] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/15/2013] [Revised: 11/25/2013] [Accepted: 12/07/2013] [Indexed: 12/31/2022]
Abstract
UNLABELLED The drugs/strategies to selectively inhibit tumor blood supply have generated interest in recent years for enhancement of cancer therapeutics. The objective of this study was to formulate tumor homing PEGylated CREKA peptide conjugated theranostic nanoparticles of DIM-C-pPhC6H5 (DIM-P) and investigate in vivo antitumor activity as well as evaluate the targeted efficiency to lung tumors using imaging techniques. DIM-P loaded Nanoparticles (NCs-D) were prepared using lipids, and DOGS-NTA-Ni and the surface of NCs-D were modified with PEGylated CREKA peptide (PCNCs-D). PCNCs-D showed 3 fold higher binding to clotted plasma proteins in tumor vasculature compared to NCs-D. PCNCs-D showed 26%±4% and 22%±5% increase in tumor reduction compared to NCs-D in metastatic and orthotopic models respectively. In-vivo imaging studies showed ~40 folds higher migration of PCNCs-Di in tumor vasculature than NCs-Di. Our studies demonstrate the role of PCNCs-D as theranostic tumor homing drug delivery and imaging systems for lung cancer diagnosis and treatment. FROM THE CLINICAL EDITOR This study demonstrates a very efficient delivery system to address lung cancer growth through blood supply inhibition.
Collapse
|